Αρχική World News HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours World News HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours Από Ogkologos - 30 Ιουλίου, 2025 765 0 Facebook Twitter Google+ Pinterest WhatsApp Real-world experience from pan-tumour testing Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Acalabrutinib 18 Ιουνίου, 2025 Targeted Therapy Based on Molecular Profiling of Malignant Mesothelioma Tumours Is... 19 Οκτωβρίου, 2020 Changes to chromosomes impact how children’s brain tumours respond to treatment 4 Νοεμβρίου, 2022 Hyperfractionated Intensity-Modulated Radiotherapy Decreases the Rate of Severe Late Complications and... 7 Μαρτίου, 2023 Φόρτωση περισσοτέρων HOT NEWS FDA Approves Device for Treatment of Osteoid Osteoma in the Extremities ESMO AI & Digital Oncology Congress 2025 Closed in Berlin under... Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma Cancer Moonshot℠ Workshop Highlights Recent Research Advances